NL-OMON39914已完成3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the Efficacy and Safety of SAR236553 (REGN727) in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C higher or equal to 160mg/dL with Their Lipid-Modifying Therapy - EFC12732 / Odyssey High FH
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 11
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with heterozygous familial hypercholesterolemia who are not adequately controlled with their lipid-modifying therapy.
排除标准
- •- Age < 18 years;- LDL-C < 160 mg/dL (< 4.14 mmol/L) at the screening visit (Week-2).;- Fasting serum triglycerides > 400 mg/dL (> 4.52 mmol/L) during the screening period.;- Known history of homozygous familial hypercholesterolemia.
研究者
相似试验
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727/Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapyinherited hyperlipidemia100274241001331710003216familial hypercholesterolemiaNL-OMON39858Sanofi-aventis18
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying Therapyfamilial hyperchomesterolemiainherited hyperlipidemia100274241001331710003216NL-OMON39622Regeneron Pharmaceuticals, Inc.100
已完成
3 期
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011hyperlipidemiehigh cholesterolHyperlipidaemiaNL-OMON37577Kowa Research Europe40
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemiahypertriglyceridemia10013317NL-OMON43654IONIS Pharmaceuticals, Inc6
已完成
4 期
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)inflamatory bowel disease10017969Ulcerative ColitisNL-OMON47815Takeda Development Centre Europe, Ltd10